Our study demonstrates that MCL1 inhibition considerably enhances response of BRCA1-mutated TNBC to the clinical PARPi olaparib and suggests that this combination should be prioritized for clinical evaluation, especially in BRCA1-mutated cancer patients with poor response to PARPi monotherapy. The gene discussed is MCL1; the disease is cancer.